InMed Pharmaceuticals Inc. (INM): Análisis de la Matriz ANSOFF [Actualizado en Ene-2025]

En el panorama dinámico de la innovación farmacéutica, Inmed Pharmaceuticals Inc. emerge como una fuerza pionera, navegando estratégicamente el complejo mundo de las terapias basadas en cannabinoides. Al elaborar meticulosamente una matriz de Ansoff integral, la compañía presenta una hoja de ruta audaz que abarca la penetración del mercado, el desarrollo, la innovación de productos y la diversificación estratégica, que promueve para revolucionar la atención médica a través de tecnologías cannabinoides de vanguardia. Sumérgete en esta exploración del enfoque visionario de Inmed, donde la precisión científica cumple con el potencial transformador.

Inmed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Penetración del mercado

Expandir la visibilidad del ensayo clínico y el reclutamiento de pacientes

Inmed Pharmaceuticals realizó 2 ensayos clínicos activos en 2022, centrándose en programas terapéuticos basados ​​en cannabinoides. Los datos de reclutamiento de pacientes mostraron 47 participantes inscritos en los estudios de epidermólisis bulosa y glaucoma.

Aumentar los esfuerzos de marketing para los profesionales de la salud

La asignación de presupuesto de marketing para 2022 fue de $ 1.2 millones, dirigido a conferencias médicas especializadas y redes profesionales.

• Asistió a 7 conferencias médicas internacionales
• Realizado 12 seminarios web específicos
• Distribuidos 5,000 paquetes de información profesional

Optimizar los procesos de fabricación

Las iniciativas de reducción de costos de fabricación lograron una mejora de la eficiencia de producción del 18% en 2022.

Fortalecer las asociaciones estratégicas

Asociaciones establecidas con 3 instituciones de investigación en 2022.

• Colaboración de investigación de la Universidad de Columbia Británica
• Programa de investigación de cannabinoides de la Universidad de Stanford
• Asociación de estudio clínico de la Universidad Metropolitana de Toronto

Inversión total de asociación de investigación: $ 850,000 en 2022.

Inmed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Desarrollo del mercado

Mercados internacionales objetivo con vías regulatorias establecidas para la terapéutica a base de cannabinoides

InMed Pharmaceuticals ha identificado mercados internacionales clave con marcos regulatorios de cannabinoides progresivos:

Explore la expansión en mercados emergentes

Mercados emergentes potenciales con regulaciones en evolución del cannabis:

• Alemania: Mercado de cannabis medicinal valorado en $ 1.5 mil millones para 2025
• Israel: $ 300 millones de potencial de mercado de cannabis medicinal
• Tailandia: Primer país asiático con legislación integral de cannabis medicinal

Desarrollar colaboraciones estratégicas

Asociaciones actuales de distribución farmacéutica:

Investigación de mercado integral

Segmentos de atención médica objetivo con un potencial de mercado significativo:

• Dermatología: $ 23.6 mil millones Global Market para 2027
• Oftalmología: potencial de mercado de $ 62.4 mil millones
• Manejo del dolor: mercado global de $ 87.2 mil millones para 2026

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Desarrollo de productos

Avance de la tubería de investigación para trastornos de la piel raros y afecciones neurológicas

Inmed Pharmaceuticals se ha centrado en el desarrollo de terapias a base de cannabinoides para enfermedades raras. A partir del cuarto trimestre de 2022, la compañía tenía 3 candidatos de drogas principales en su tubería de investigación.

Desarrollar nuevos mecanismos de administración de medicamentos

InMed ha invertido $ 2.3 millones en el desarrollo de tecnologías de administración de medicamentos patentados en 2022.

• Investigación tópica de formulación de cannabinoides
• Sistemas avanzados de entrega transdérmica
• Plataformas de administración de medicamentos neurológicos dirigidos

Invierta en plataformas de investigación avanzadas

Gastos de investigación y desarrollo para 2022: $ 4.7 millones.

Mejorar la cartera de propiedades intelectuales

A diciembre de 2022, Inmed celebró 12 solicitudes de patentes activas a nivel mundial.

• 6 Patentes en mecanismos de suministro de cannabinoides
• 4 Patentes en aplicaciones terapéuticas de enfermedades raras
• 2 patentes en nuevas técnicas de formulación de drogas

Inmed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Diversificación

Aplicaciones potenciales de tecnologías cannabinoides en sectores de atención médica adyacentes

InMed Pharmaceuticals reportó $ 3.2 millones en gastos de investigación y desarrollo para el cuarto trimestre de 2022. La plataforma de tecnología cannabinoides de la compañía se centra en aplicaciones de dermatología y neurología.

Oportunidades estratégicas de inversión y adquisición

La posición de efectivo de Inmed era de $ 11.6 millones al 31 de diciembre de 2022, lo que permite posibles inversiones de dominio de biotecnología.

• Presupuesto de adquisición de biotecnología: aproximadamente $ 5-7 millones
• Sectores objetivo: terapéutica de enfermedades raras
• Criterios de inversión: empresas de etapa preclínica

Posibles iniciativas de investigación spin-off

Oportunidades de licencia tecnológica

La cartera de patentes de Inmed incluye 12 patentes otorgadas en múltiples jurisdicciones.

• Ingresos potenciales de licencia: $ 2-4 millones anuales
• Empresas objetivo: las 20 principales empresas farmacéuticas
• Enfoque de licencia: tecnologías terapéuticas a base de cannabinoides

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Market Penetration

The BayMedica commercial segment realized sales of $4.9M for the fiscal year ended June 30, 2025. This represented an increase of $0.34M, or 8%, compared to the fiscal year ended June 30, 2024.

For the three months ended March 31, 2025, BayMedica generated revenues of $1.26 million, matching the 8% growth rate seen for the full fiscal year 2025 period.

The broader market context for minor cannabinoid-infused edibles showed a 47% year-over-year growth in 2023, totaling $391 million in sales across ten regulated states.

The company's cash position as of June 30, 2025, was $11.1M, which supports funding planned operating expenses into the fourth quarter of calendar year 2026, depending on BayMedica revenues.

The following table summarizes the recent financial performance of the BayMedica commercial segment to frame the market penetration goals:

Actions to drive sales beyond the 8% fiscal 2025 growth rate include specific commercial strategies:

• Offer aggressive volume-based pricing to secure larger B2B supply contracts.
• Expand direct sales force coverage to capture more US health and wellness ingredient customers.
• Launch targeted digital campaigns emphasizing BayMedica's proprietary manufacturing quality.
• Target a revenue increase exceeding the $0.34M achieved between fiscal 2024 and fiscal 2025.

The proprietary manufacturing quality is supported by the development of a robust pilot-scale process for THCV production.

The company's stock price as of October 31, 2025, was $1.88, with a market capitalization of $4.48M.

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Market Development

You're looking at how InMed Pharmaceuticals Inc. can take its existing rare cannabinoid ingredients and commercial structure, BayMedica, and push them into new geographic areas or new customer types. This is Market Development, and it needs cash to fund the expansion efforts.

Initiate regulatory filings to commercialize rare cannabinoids in key European Union markets.

The ability to fund the necessary regulatory steps for EU market entry is supported by the balance sheet as of the end of fiscal year 2025. InMed had $11.1 million in cash, cash equivalents, and short-term investments on June 30, 2025. This cash position is expected to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026. The company recorded a net loss of $8.2 million for the year ended June 30, 2025.

Secure distribution partnerships to introduce BayMedica products into Asian functional food sectors.

The foundation for this expansion is the existing commercial business, BayMedica. For the year ended June 30, 2025, the BayMedica segment realized sales of $4.9 million. This represented an increase of $0.34 million, or 8%, compared to the year ended June 30, 2024. The business generates approximately 40 percent gross margins selling to the global health and wellness ingredient markets.

Target new B2B segments like high-end cosmeceuticals with existing rare cannabinoid ingredients.

Expanding into higher-value B2B segments like cosmeceuticals requires demonstrating the commercial viability of the current product line. The BayMedica Commercial segment reported an 8% increase in sales for the three months ended March 31, 2025, compared to the same period in 2024. However, the cost of sales for that segment increased by 23% for the same period, primarily due to an increase in sales of lower margin products. The overall annual revenue for fiscal year 2025 ending June 30, 2025, was $4.94 million, a 7.5% increase year-over-year.

Present BayMedica's commercial portfolio at international trade shows to find new global buyers.

Trade show presence is a direct sales and marketing cost that needs to be weighed against revenue generation. For the quarter ending September 30, 2025 (Q3 2025), revenue was reported at $1.12 million, which was up 11.43% year-over-year. The trailing twelve months ending September 30, 2025, showed total revenue of $4.80 million.

Here's a quick look at the key financial metrics supporting the commercial arm's ability to fund market development activities:

The performance of the BayMedica segment in fiscal 2025 shows a clear, albeit modest, growth trajectory:

• BayMedica segment sales growth for FY2025: 8%.
• Q1 2025 sales increase year-over-year: 8%.
• Q3 2025 sales year-over-year increase: 11.43%.
• Q3 2025 sales quarter-over-quarter change: down 14.1%.
• Increase in Cost of Sales for Q1 2025: 23%.

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Product Development

You're looking at the core of InMed Pharmaceuticals Inc.'s (INM) growth engine-the product pipeline-which is squarely in the Product Development quadrant of the Ansoff Matrix. This means maximizing value from existing markets (pharmaceutical indications) by bringing new or improved products to them.

For INM-901, targeting Alzheimer's disease (AD), the focus has shifted to the final preclinical steps before human trials. As of November 2025, the company announced the successful completion of pharmacokinetic studies in large animal models for the oral formulation. This is a major step, as the data demonstrated robust bioavailability over a seven-day dosing period. The next required action is advancing into Investigational New Drug (IND)-enabling studies, which is being supported by preparing for a pre-IND meeting with the U.S. Food and Drug Administration (FDA) and completing Chemistry, Manufacturing, and Controls (CMC) development to scale supply.

The financial underpinning for this work is clear. InMed reported a cash balance of \$11.1M as of June 30, 2025. A portion of this balance is earmarked for optimizing the oral formulation of INM-901, which is a critical activity preceding IND-enabling studies. This cash position is expected to support planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026.

For INM-089, targeting dry Age-related Macular Degeneration (AMD), the preclinical work is being finalized to prepare for a first-in-human trial. The company selected an intravitreal (IVT) formulation for continued development in February 2025. This IVT formulation showed successful delivery in preclinical studies at doses up to 10 times the calculated safety margin relative to the therapeutic dose level. Furthermore, a series of dose-ranging in vivo studies were recently completed, with the resulting information guiding the selection of doses for pivotal preclinical toxicology studies, which are the next step toward an IND filing.

The development of INM-755 for Epidermolysis Bullosa (EB) is currently focused on securing external funding to move into Phase 3, as the Phase 2 trial is complete. The company is actively seeking strategic pharmaceutical partners to fund and advance this program.

Here is a snapshot of the key development activities and financial context:

The allocation of capital directly supports these product advancements. The investment into optimizing the oral formulation of INM-901 is a direct use of the company's liquidity.

• Cash balance as of June 30, 2025: \$11.1M.
• Expected cash runway into: Q4 2026.
• INM-901 optimization is a planned use of a portion of this cash.
• INM-901 preclinical work included a seven-day dosing study.

To be fair, the path from completing PK studies to starting IND-enabling studies requires rigorous documentation and regulatory alignment. Finance: finalize the budget allocation for INM-901 formulation optimization by next Tuesday.

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Diversification

Initiate a new drug discovery program targeting a novel, high-unmet-need oncology indication.

The current pharmaceutical focus includes INM-901 for Alzheimer's disease and INM-089 for dry Age-related Macular Degeneration, both proprietary small molecule drug candidates. The cash position as of June 30, 2025, was $11.1M, with an expected runway into the fourth quarter of calendar year 2026. This cash level must support the advancement of existing programs while funding a new oncology initiative.

Acquire a complementary small-molecule platform outside of the current CB1/CB2 receptor focus.

InMed Pharmaceuticals Inc.'s existing pipeline is noted for targeting the CB1/CB2 receptors. Diversification here would mean adding a platform that operates outside this established mechanism. The fiscal year 2025 net loss was $8.2M, compared to $7.7M in the prior year. Any acquisition would need to be financed against this current burn rate and cash reserve.

Leverage the IntegraSyn manufacturing technology to produce non-cannabinoid, high-value Active Pharmaceutical Ingredients (APIs).

The IntegraSyn system was developed to produce pharmaceutical-grade, bio-identical cannabinoids, achieving a cannabinoid yield of 5 g/L. To pivot this technology to non-cannabinoid APIs would require retooling or proving the modularity of the process for different substrates. Research and development expenses for the year ended June 30, 2025, totaled $2.9M.

Establish a joint venture with a major biotech firm to co-develop a new therapeutic in a non-CNS/Ocular market.

Current pharmaceutical development is centered on CNS (Alzheimer's) and Ocular (AMD) indications. A joint venture outside these areas represents a significant market diversification. BayMedica, the commercial segment, realized sales of $4.9M for the year ended June 30, 2025, an increase of 8% year-over-year. This commercial revenue stream provides a financial base, though General and administrative expenses rose to $6.6M in FY2025 from $5.8M in FY2024.

Here's the quick math on recent financial performance:

The current pipeline focus areas and associated data points are:

• INM-901 targets Alzheimer's disease pathology.
• INM-089 demonstrated neuroprotection in dry Age-related Macular Degeneration.
• IntegraSyn achieved a cannabinoid yield of 5 g/L.
• Cash on hand as of June 30, 2025, was $11.1M.
• Market Capitalization as of May 2025 was $2.83M.